Invention Grant
- Patent Title: Antigen binding protein against HER3
-
Application No.: US16326864Application Date: 2017-09-15
-
Publication No.: US11008402B2Publication Date: 2021-05-18
- Inventor: Roland Kontermann , Lisa Schmitt , Meike Hutt , Oliver Seifert , Monilola Olayioye , Michael Hust , Stefan Dübel , Jonas Zantow
- Applicant: UNIVERSITÄT STUTTGART
- Applicant Address: DE Stuttgart
- Assignee: UNIVERSITÄT STUTTGART
- Current Assignee: UNIVERSITÄT STUTTGART
- Current Assignee Address: DE Stuttgart
- Agency: McDonnell Boehnen Hulbert & Berghoff LLP
- Priority: EP16188871 20160915
- International Application: PCT/EP2017/073328 WO 20170915
- International Announcement: WO2018/050848 WO 20180322
- Main IPC: A61K39/00
- IPC: A61K39/00 ; C07K16/32 ; C07K16/28 ; C07K16/30 ; A61P35/00 ; A61K39/395

Abstract:
The invention provides an antigen-binding protein that specifically binds to a conformational epitope formed by domain III & IV of human epidermal growth factor receptor 3 (HER3) and antigen-binding proteins which compete therewith for binding, as well as fusion protein or conjugate comprising these. The invention also provides nucleic acid molecule comprising a sequence encoding said antigen binding proteins, vectors comprising the nucleic acid, and cells and pharmaceuticals comprising the antigen binding protein, the fusion protein, the nucleic acid, or the vector. The invention also provides the antigen binding protein, the fusion protein or conjugate, the nucleic acid, the vector, the cell, or the pharmaceutical for use as a medicament. The invention further provides a method of inhibiting tumor growth or treating cancer, comprising administering a therapeutically effective amount of the antigen binding protein, the fusion protein or conjugate, the nucleic acid, the vector, the cell, or the pharmaceutical.
Public/Granted literature
- US20190194350A1 ANTIGEN BINDING PROTEIN AGAINST HER3 Public/Granted day:2019-06-27
Information query